Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TELA Bio, Inc. (TELA)

TELA Bio receives FDA 510(k) clearance for Liora Monofilament Scaffold

Neutral Impact 3 of 5 product/contract Written later

TELA Bio said the U.S. Food and Drug Administration granted 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. The company said Liora is the first implant fully developed in its ISO 8 certified cleanroom in Malvern, PA, and that it expands TELA Bio's footprint in the soft tissue reconstruction market. The filing does not include financial figures or sales expectations for the product.

Key points

  • FDA granted 510(k) clearance for the Liora Monofilament Scaffold, announced October 5, 2026
  • Liora is described as a fully resorbable surgical mesh device for soft tissue reinforcement
  • Liora is the first implant fully developed in the company's ISO 8 certified cleanroom in Malvern, PA
  • More details are expected on the third quarter earnings call, expected in early November

The filing

CompanyTELA Bio, Inc. (TELA)
Form8-K, current report
Filed with the SECOct 5, 2026, 8:05 AM ET
Accession number0001104659-26-113506

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.